BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fan H, Atiya HI, Wang Y, Pisanic TR, Wang TH, Shih IM, Foy KK, Frisbie L, Buckanovich RJ, Chomiak AA, Tiedemann RL, Rothbart SB, Chandler C, Shen H, Coffman LG. Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis. Cell Rep 2020;33:108473. [PMID: 33296650 DOI: 10.1016/j.celrep.2020.108473] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Xu M, Zhang T, Xia R, Wei Y, Wei X. Targeting the tumor stroma for cancer therapy. Mol Cancer 2022;21:208. [PMID: 36324128 DOI: 10.1186/s12943-022-01670-1] [Reference Citation Analysis]
2 Pressimone C, Frisbie L, Dyer E, Baruwal R, Croix CS, Watkins S, Calderone M, Gorecki G, Javed Z, Atiya HI, Hempel N, Pearson A, Coffman L. Carcinoma associated mesenchymal stem cells promote ovarian cancer metastasis by increasing tumor heterogeneity through direct mitochondrial transfer.. [DOI: 10.1101/2022.09.21.506345] [Reference Citation Analysis]
3 Li JP, Liu YJ, Zeng SH, Gao HJ, Chen YG, Zou X. Identification of COX4I2 as a hypoxia-associated gene acting through FGF1 to promote EMT and angiogenesis in CRC. Cell Mol Biol Lett 2022;27:76. [PMID: 36064310 DOI: 10.1186/s11658-022-00380-2] [Reference Citation Analysis]
4 Ramuta TŽ, Kreft ME. Mesenchymal Stem/Stromal Cells May Decrease Success of Cancer Treatment by Inducing Resistance to Chemotherapy in Cancer Cells. Cancers 2022;14:3761. [DOI: 10.3390/cancers14153761] [Reference Citation Analysis]
5 Zhou W, Hinoue T, Barnes B, Mitchell O, Iqbal W, Lee SM, Foy KK, Lee K, Moyer EJ, Vanderark A, Koeman JM, Ding W, Kalkat M, Spix NJ, Eagleson B, Pospisilik JA, Szabó PE, Bartolomei MS, Vander Schaaf NA, Kang L, Wiseman AK, Jones PA, Krawczyk CM, Adams M, Porecha R, Chen BH, Shen H, Laird PW. DNA methylation dynamics and dysregulation delineated by high-throughput profiling in the mouse. Cell Genomics 2022;2:100144. [DOI: 10.1016/j.xgen.2022.100144] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Taylor SE, Chan DK, Yang D, Bruno T, Lieberman R, Siddiqui J, Soong TR, Coffman L, Buckanovich RJ. Shifting the Soil: Metformin Treatment Decreases the Protumorigenic Tumor Microenvironment in Epithelial Ovarian Cancer. Cancers 2022;14:2298. [DOI: 10.3390/cancers14092298] [Reference Citation Analysis]
7 Xie T, Tan M, Gao Y, Yang H. CRABP2 accelerates epithelial mesenchymal transition in serous ovarian cancer cells by promoting TRIM16 methylation via upregulating EZH2 expression. Environ Toxicol 2022. [PMID: 35442568 DOI: 10.1002/tox.23542] [Reference Citation Analysis]
8 Zhou W, Hinoue T, Barnes B, Mitchell O, Iqbal W, Lee SM, Foy KK, Lee K, Moyer EJ, Vanderark A, Koeman JM, Ding W, Kalkat M, Spix NJ, Eagleson B, Pospisilik JA, Szabó PE, Bartolomei MS, Vander Schaaf NA, Kang L, Wiseman AK, Jones PA, Krawczyk CM, Adams M, Porecha R, Chen BH, Shen H, Laird PW. DNA Methylation Dynamics and Dysregulation Delineated by High-Throughput Profiling in the Mouse.. [DOI: 10.1101/2022.03.24.485667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wilson MR, Reske JJ, Koeman J, Adams M, Joshi NR, Fazleabas AT, Chandler RL. SWI/SNF Antagonism of PRC2 Mediates Estrogen-Induced Progesterone Receptor Expression. Cells 2022;11:1000. [PMID: 35326450 DOI: 10.3390/cells11061000] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sun S, Yu F, Xu D, Zheng H, Li M. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy. Biochim Biophys Acta Rev Cancer 2022;:188700. [PMID: 35217116 DOI: 10.1016/j.bbcan.2022.188700] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Liu M, Yang J, Xu B, Zhang X. Tumor metastasis: Mechanistic insights and therapeutic interventions. MedComm (2020) 2021;2:587-617. [PMID: 34977870 DOI: 10.1002/mco2.100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
12 Ding D, Wang K. Role of cancer-associated mesenchymal stem cells in the tumor microenvironment: A review. Tzu Chi Med J 2022;0:0. [DOI: 10.4103/tcmj.tcmj_138_22] [Reference Citation Analysis]
13 Smith JP, Corces MR, Xu J, Reuter VP, Chang HY, Sheffield NC. PEPATAC: an optimized pipeline for ATAC-seq data analysis with serial alignments. NAR Genom Bioinform 2021;3:lqab101. [PMID: 34859208 DOI: 10.1093/nargab/lqab101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
14 Freeman DW, Rodrigues Sousa E, Karkampouna S, Zoni E, Gray PC, Salomon DS, Kruithof-de Julio M, Spike BT. Whence CRIPTO: The Reemergence of an Oncofetal Factor in 'Wounds' That Fail to Heal. Int J Mol Sci 2021;22:10164. [PMID: 34576327 DOI: 10.3390/ijms221810164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Li W, Yang J, Zheng P, Li H, Zhao S. The Origins and Generation of Cancer-Associated Mesenchymal Stromal Cells: An Innovative Therapeutic Target for Solid Tumors. Front Oncol 2021;11:723707. [PMID: 34513701 DOI: 10.3389/fonc.2021.723707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Gagliano T, Brancolini C. Epigenetic Mechanisms beyond Tumour-Stroma Crosstalk. Cancers (Basel) 2021;13:914. [PMID: 33671588 DOI: 10.3390/cancers13040914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
17 Ramarao-Milne P, Kondrashova O, Barry S, Hooper JD, Lee JS, Waddell N. Histone Modifying Enzymes in Gynaecological Cancers. Cancers (Basel) 2021;13:816. [PMID: 33669182 DOI: 10.3390/cancers13040816] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]